289 related articles for article (PubMed ID: 31477881)
1. Phase I trials as valid therapeutic options for patients with cancer.
Adashek JJ; LoRusso PM; Hong DS; Kurzrock R
Nat Rev Clin Oncol; 2019 Dec; 16(12):773-778. PubMed ID: 31477881
[TBL] [Abstract][Full Text] [Related]
2. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
[TBL] [Abstract][Full Text] [Related]
3. New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Ringel MD
J Clin Endocrinol Metab; 2021 Jan; 106(1):e382-e388. PubMed ID: 32977343
[TBL] [Abstract][Full Text] [Related]
4. [TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].
Foughali R; Marie JC
Med Sci (Paris); 2020 Jan; 36(1):77-79. PubMed ID: 32014103
[No Abstract] [Full Text] [Related]
5. [Bispecific antibodies, novel therapeutic candidates harnessing the immune system].
Chames P; Wurch T
Med Sci (Paris); 2019 Dec; 35(12):1072-1082. PubMed ID: 31903920
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Advances in Oncology.
Liu J; Pandya P; Afshar S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670524
[TBL] [Abstract][Full Text] [Related]
7. [Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes].
Manier S; de Charette de la Contrie M; Hieulle J; Daniel A; Facon T
Presse Med; 2019; 48(7-8 Pt 1):825-831. PubMed ID: 31447337
[TBL] [Abstract][Full Text] [Related]
8. [New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].
Champiat S; Soria JC
Med Sci (Paris); 2017; 33(6-7):563-564. PubMed ID: 28990546
[No Abstract] [Full Text] [Related]
9. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
10. Awaiting a new era of cancer immunotherapy.
Hong CW; Zeng Q
Cancer Res; 2012 Aug; 72(15):3715-9. PubMed ID: 22815525
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
12. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
13. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.
Vignot S; Martin M; Albin N; Schurtz C; Chapel E
Ann Oncol; 2019 Nov; 30(11):1694-1696. PubMed ID: 31501860
[No Abstract] [Full Text] [Related]
14. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
15. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
16. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
17. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
18. Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives.
Amodru V; Garcia ME; Libe R; Brue T; Reznik Y; Castinetti F
Ann Endocrinol (Paris); 2021 Feb; 82(1):52-58. PubMed ID: 33279475
[TBL] [Abstract][Full Text] [Related]
19. [Research evolutions in immuno-oncology and their impact on the management of patients treated with immunotherapy].
Caux C
Bull Cancer; 2020 Jan; 107(1):6-9. PubMed ID: 31954504
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies.
Halpenny D; O'Dwyer E; Girshman J; Ginsberg MS
J Thorac Imaging; 2020 Jan; 35(1):26-36. PubMed ID: 31855947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
